ArticleCureus2026
Antiphospholipid Antibodies in Severe COVID-19: Frequency, Clinical Features, and 12-Week Follow-Up.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSevere COVID-19 is characterized by a hypercoagulable state and elevated thrombotic risk, potentially linked to antiphospholipid antibodies (APLAs). The prevalence and clinical significance of APLAs in critically ill patients, particularly in low- and middle-income countries such as Bangladesh, remain unknown.
methodsWe conducted a prospective observational study among 100 adult patients admitted with severe COVID-19 to tertiary hospitals in Bangladesh between June 2021 and February 2022. We measured APLAs (IgM and IgG) and anticardiolipin antibodies (aCL; IgM and IgG) in serum samples obtained within 48 hours of admission. Patients with initially positive antibodies underwent follow-up testing at 12 weeks. We collected demographic, clinical, and laboratory data, along with thromboembolic events. Statistical analysis included paired t-tests and effect size estimation.
resultsOf the 100 patients prospectively enrolled, 57 were men, and the mean age was 60 (± 13.4) years. A total of 30 patients tested positive for at least one antibody at baseline. We observed a major decrease in APLA levels between baseline and week 12. Mean APLA IgM decreased from 13.95±10.53 to 5.12±6.60 (p=0.002) and APLA IgG levels from 18.8±37.42 to 5.64±5.22 (p=0.048). Similarly, aCL IgM declined from 16.68±9.75 to 5.49±6.73 (p<0.001), and aCL IgG dropped from 8.90±8.22 to 4.35±3.66 (p=0.011), both of which were statistically significant. Only two antibody-negative patients presented with acute myocardial infarction.
conclusionWe detected APLAs in one third of patients with severe COVID-19; however, they were not associated with clinical thromboembolic events and decreased markedly over time. These findings indicate that APLA responses during acute COVID-19 are largely transient and may not be useful for predicting thrombotic risk. Our findings do not support routine APLA testing during the acute phase of COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.